Dominick C. Colangelo

Director, President & Chief Executive Officer at Vericel Corp.

Dominick C. Colangelo

Dominick C. Colangelo

Director, President & Chief Executive Officer at Vericel Corp.

Overview
Career Highlights

Vericel Corp.
Promedior, Inc.

RelSci Relationships

1091

Primary Location

Indianapolis, IN, United States

Number of Boards

2

Birthday

1964

Age

54

Relationships
RelSci Relationships are individuals Dominick C. Colangelo likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at QuatRx Pharmaceuticals Co.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Emisphere Technologies, Inc.

Relationship likelihood: Strong

Chief Strategy Officer at Vineti, Inc.

Relationship likelihood: Strong

Chief Financial Officer at Acceleron Pharma, Inc.

Relationship likelihood: Strong

Former Senior Vice President & Chief Scientific Officer at Warner-Lambert Co.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Sigilon, Inc.

Relationship likelihood: Strong

Chairman & Chief Executive Officer at ContraFect Corp.

Relationship likelihood: Strong

Former President & Chief Executive Officer at Novavax, Inc.

Relationship likelihood: Strong

Founder at Trellis Bioscience LLC

Relationship likelihood: Strong

Co-Founder at SetPoint Medical Corp.

Relationship likelihood: Strong

Paths to Dominick C. Colangelo
Potential Connections via
Relationship Science
You
Dominick C. Colangelo
Director, President & Chief Executive Officer at Vericel Corp.
Education
BS
Class of 1986

University at Buffalo, The State University of New York, also commonly known as the University of Buffalo (abbreviated UB), University of Buffalo or SUNY Buffalo, is a public research university with multiple campuses located in Buffalo and Amherst, New York, United States. The university was founded in 1846 as a private college, but in 1962 was absorbed into the State University of New York (SUNY) system. By enrollment, UB is the largest of SUNY's four comprehensive university centers, and also the largest public university in the northeastern United States (comprising New York state and the New England region). In addition, by either endowment or research funding, UB is also the largest one of SUNY's four comprehensive flagship university centers.

Duke University School of Law (also known as Duke Law School or Duke Law) is the law school and a constituent academic unit of Duke University, Durham, North Carolina, United States. One of Duke's 10 schools and colleges, the School of Law began as the Trinity College School of Law in 1868.

Graduate Degree

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Career History
Director, President & Chief Executive Officer
2013 - Current

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function. Its product portfolio include MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns comprising a total body surface area of greater than or equal to 30%. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

President, Chief Executive Officer & Director
2008 - 2012

Promedior, Inc. operates as a clinical-stage immunotherapy company that develops targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that acts through a unique anti-fibrotic immunotherapy mechanism to activate a regulatory switch upstream in the fibrosis cascade. The company was founded by Richard H. Gomer and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

Managing Director
Prior - 2005

Lilly Ventures Management Co. focuses on investments in the biotechnology, medical technology and healthcare information technology sectors. The firm manages four funds: the e.Lilly Venture Fund, the Lilly BioVenture Fund, the Lilly MedTech Venture Fund and the Lilly Asian Ventures Fund.The e.Lilly Venture Fund targets investments in early- to development-stage start-up companies with e-business solutions that focus on the research, development and commercialization of pharmaceuticals. Investments range up to $3 million.The Lilly BioVenture Fund invests in early-stage biotechnology companies with pioneering drug discovery and development technologies and novel therapies.The Lilly MedTech Venture Fund targets investments in companies that are developing emerging technologies in the medical technology sector. The fund targets companies with innovative diagnostic technologies and therapeutic devices and combination products incorporating pharmaceuticals, medical devices or diagnostics. Initial investments range up to $5 million.The Lilly Asian Ventures makes venture capital investments in life science companies with strong management teams and innovative technology and/or business models. The fund targets companies at various stages of development from start-up to commercialization. Specific areas of interest include biotechnology and pharmaceuticals, medical devices and diagnostics and healthcare services. Their focus is mainly on opportunities in China but they will consider investment opportunities elsewhere in east and south Asia.

Boards & Committees
President & Chief Executive Officer & Director
2013 - Current

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function. Its product portfolio include MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns comprising a total body surface area of greater than or equal to 30%. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

President, Chief Executive Officer & Director
2008 - 2012

Promedior, Inc. operates as a clinical-stage immunotherapy company that develops targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that acts through a unique anti-fibrotic immunotherapy mechanism to activate a regulatory switch upstream in the fibrosis cascade. The company was founded by Richard H. Gomer and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

Transactions
Details Hidden

Promedior, Inc. raised money in a private placement transaction

Details Hidden

Promedior, Inc. raised money in a private placement transaction

Details Hidden

Promedior, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.